Business Context and Reporting Period
This Form 6-K filing by Innate Pharma S.A., a foreign private issuer, covers the month of November 2022. The report, dated November 7, 2022, serves as a vehicle to disseminate a press release (Exhibit 99.1) to U.S. investors. The company is headquartered in Marseille, France, and files annual reports under Form 20-F.
Financial Metrics
The provided filing text does not contain specific financial data. It is a cover document referencing an external press release. Consequently, values for revenue, profit, cash flow, margins, debt, and liquidity are not present in this text.
Material Changes
The filing text does not provide details on material changes versus prior periods. The content is limited to the submission of a press release dated November 7, 2022, without summarizing its financial or operational impact within this document.
Guidance, Outlook, and Risks
Management commentary, guidance, outlook, risks, contingencies, and unusual items are not detailed in this filing text. The document only confirms the authorization of the report by Mondher Mahjoubi, Chairman of the Executive Board and Chief Executive Officer.
Key Facts for Investor Verification
- Verify the content of the referenced Press Release dated November 7, 2022 (Exhibit 99.1) for specific operational or financial updates.
- Confirm the company's status as a foreign private issuer filing under Form 20-F.
- Note that this specific Form 6-K text contains no numerical financial data.